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A B S T R A C T
Objectives: The aim of this study was to define the relationship between age and response to tigecycline
among patients treated for complicated skin and soft-tissue infections (cSSTIs) and complicated intra-
abdominal infections (cIAIs).
Methods: Pooled data derived from five European observational studies on the use of tigecycline (July
2006–October 2011), either as monotherapy or in combination with other antibiotics, for the treatment of
cSSTI or cIAI were used in the analysis.
Results: The total population (N = 1782 patients) was divided into three age categories: <65 years (804
patients); 65–80 years (836 patients) and >80 years (139 patients) (data unknown/missing for 3
patients). The overall mean Acute Physiology and Chronic Health Evaluation (APACHE) II score for
patients with cSSTI and cIAI was 15.0  7.9 and 16.9  7.6, respectively, and the overall mean Sequential
Organ Failure Assessment (SOFA) score was 5.8  3.9 and 7.0  4.2, respectively. Overall, patients with
cSSTI and cIAI in the three age groups showed a good response to tigecycline treatment (76.2–80.0% and
69.2–81.1%, respectively) with patients aged 80 years showing higher response rates. Patients with cIAI
appeared to be at greater risk for all types of adverse events compared with those with cSSTI, particularly
in the older age groups.
Conclusion: In these real-life studies, tigecycline, either alone or in combination, achieved favourable
clinical response rates in all age categories of patients with cSSTIs and cIAIs with a high severity of illness.
© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Accounting for approximately 19.2% of the total population in
Europe according to data from 2016, elderly people (aged 65
years) have relatively high use of healthcare resources, and age is a
risk factor for poor outcome [1–3]. Several factors may contribute
to poor outcomes in the elderly population with infections such as
complicated skin and soft-tissue infection (cSSTI) and complicated
intra-abdominal infection (cIAI). Challenges in antibiotic treat-
ment of infections in the elderly include increased risk of infection* Corresponding author.
E-mail address: matteo.bassetti@asuiud.sanita.fvg.it (M. Bassetti).
https://doi.org/10.1016/j.jgar.2019.03.018
2213-7165/© 2019 The Author(s). Published by Elsevier Ltd on behalf of International Soc
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).owing to age-related immune degeneration [4], more frequent
exposure to the healthcare system and residence in chronic
healthcare institutions leading to an increased risk of multidrug-
resistant infections [5,6], increased vulnerability to antibiotic
adverse drug reactions, heightened risk of Clostridioides (formerly
Clostridium) difficile infection [6] and different pharmacokinetics/
pharmacodynamics [7].
cSSTIs are among the most commonly encountered infections
in the hospital setting and encompass a heterogeneous group of
infections affecting the deep soft tissue [8,9]. Some of the most
common pathogens implicated in cIAI and cSSTI are multidrug-
resistant, including extended-spectrum β-lactamase-producing
Escherichia coli in cIAI and methicillin-resistant Staphylococcus
aureus (MRSA) in cSSTI [10,11].iety for Antimicrobial Chemotherapy. This is an open access article under the CC BY-
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approved for the treatment of cSSTI (with the exception of diabetic
foot infection) and cIAI [12,13]. In the USA, tigecycline is also
approved for the treatment of community-acquired bacterial
pneumonia [12]. The efficacy of tigecycline versus other anti-
microbials for the treatment of cSSTIs and cIAIs has been
demonstrated in double-blind, randomised, phase III randomised
clinical trials [14,15]. Real-world data on the use of tigecycline
obtained through five non-interventional, observational studies
conducted in four European countries [Germany, Italy, France and
Spain (two studies, Spain-1 and Spain-2)] from July 2006 to
October 2011 were pooled and analysed to describe the prescribing
patterns for tigecycline [16], its efficacy in the treatment of cSSTIs
[8], its efficacy in the treatment of cIAIs [17], its safety and
tolerability in the treatment of cSSTIs and cIAIs [18], and the
resistance mechanisms and epidemiology of multidrug-resistant
pathogens in Europe [19].
The analysis reported here utilises data collected from the
aforementioned observational studies to define the relationship
between age and response to tigecycline among patients treated
for cSSTI and cIAI.
2. Materials and methods
2.1. Patients
This analysis included data collected by hospital-based
physicians in five non-interventional, observational studies
conducted in Europe (July 2006–October 2011). The study
designs, together with inclusion and exclusion criteria for each
study, are described in Table 1 of Bassetti et al. [16]. Owing to the
observational nature of the studies, there were few inclusion/Table 1
Baseline characteristics of patients included in the analysis.





Male sex [n (%)] 83 (70.9) 62 (54.4) 
Mean BMI (kg/m2) 28.4 28.2 
Clinical characteristics
ICU admission [n (%)] 42 (36.2) 38 (33.3) 
Missing/unknown (n) 0 1 
APACHE II score 15 [n (%)] 45 (52.9) 53 (54.1) 
Missing/unknown (n) 19 12 
SOFA score (only France and Spain-2) <7 [n (%)] 14 (60.9) 5 (55.6) 
Missing/unknown (n) 0 0 
Co-morbidities
1 co-morbidity [n (%)] 99 (84.6) 109 (95.6) 
Co-morbid conditions [n/N (%)]
COPD 22/94 (23.4) 30/107 (28
Diabetes mellitus 44/99 (44.4) 69/109 (63
Heart failure 27/94 (28.7) 49/107 (45
Hypertension 50/80 (62.5) 80/90 (88.9
Obesity 32/78 (41.0) 22/87 (25.3
Renal failure 32/99 (32.3) 57/109 (52.
Smoker 29/80 (36.3) 12/90 (13.3
Baseline pathogens [n/N (%)]
Polymicrobial infection 35/102 (34.3) 29/95 (30.5
Anaerobes 13/78 (16.7) 8/77 (10.4)
Gram-negative bacilli 32/78 (41.0) 28/ (36.4) 
Gram-positive cocci 60/78 (76.9) 65/77 (84.4
Site of infection acquisition [n (%)]
Nosocomial infectiona 58 (50.0) 67 (58.8) 
Community-acquired infectiona 58 (50.0) 47 (41.2) 
Previous antibiotic therapy [n (%)] 87 (75.0) 81 (71.1) 
cSSTI, complicated skin and soft-tissue infection; cIAI, complicated intra-abdominal infec
Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; COPD, chronic
a Includes non-cSSTI and non-cIAI indications such as pneumonia and bacteraemia.exclusion criteria or protocol specifications, except for the
receipt of tigecycline. Diagnosis of cSSTI and cIAI was at the
discretion of the physician with no independent adjudication or
external safety committee. SSTIs are commonly defined as
complicated when surgical intervention is required and/or the
infectious process is suspected or confirmed to involve deeper
soft tissue such as the fascia and/or muscle layers. cIAIs are
commonly defined as infections that extend into the peritoneal
space and are associated with either abscess formation or
peritonitis [8,17]. For further information about the definition of
cSSTI and cIAI, refer to Montravers et al. [8] and Eckmann et al.
[17], respectively. Hospitalised patients were included if they
received tigecycline for any indication during the study period,
with the exception of the Spain-1 study that included only
patients with a diagnosis of cSSTI or cIAI. Two studies (France
and Spain-2) included only patients admitted to the intensive
care unit (ICU) [8,17]. Administration of tigecycline, dosage,
duration of treatment and prescription of other antibiotics
during or after the initiation of tigecycline were at the
physician’s discretion. All concomitant medications were
permitted [8,17]. The total population was divided into three
age categories for the purpose of this analysis: <65 years; 65–80
years; and >80 years.
This research was conducted in accordance with the Declara-
tion of Helsinki as well as all national and institutional standards.
The protocol of each study was approved by the local ethics
committee or institutional review board. Owing to the non-
interventional observational nature of the studies, written
informed consent was not required for enrolment in the studies
in Germany, Italy and Spain-2. Written informed consent was
obtained from patients prior to participation in the studies in









12 (52.2) 219 (59.2) 209 (58.4) 28 (51.9)
25.7 26.9 27.9 27.1
7 (34.4) 201 (54.3) 213 (59.7) 27 (50.0)
0 0 1 1
16 (72.7) 138 (48.6) 100 (35.7) 18 (37.5)
1 49 41 2
0 25 (45.5) 19 (39.6) 4 (80.0)
0 0 2 0
23 (100) 314 (84.9) 325 (90.8) 47 (87.0)
.0) 6/23 (26.1) 36/294 (12.2) 65/303 (21.5) 10/46 (21.7)
.3) 13/23 (56.5) 74/314 (23.6) 116/324 (35.8) 18/47 (38.3)
.8) 13/23 (56.5) 41/294 (13.9) 79/303 (26.1) 17/46 (37.0)
) 15/16 (93.8) 94/228 (41.2) 169/234 (72.2) 25/32 (78.1)
) 2/16 (12.5) 53/233 (22.7) 74/242 (30.6) 10/32 (31.3)
3) 13/23 (56.5) 55/314 (17.5) 95/324 (29.3) 20/47 (42.6)
) 0/0 66/228 (28.9) 21/234 (9.0) 0/0
) 6/16 (37.5) 145/297 (48.8) 142/285 (49.8) 17/38 (44.7)
 4/12 (33.3) 56/216 (25.9) 55/217 (25.3) 2/28 (7.1)
5/12 (41.7) 137/216 (63.4) 137/217 (63.1) 21/28 (75.0)
) 9/12 (75.0) 161/216 (74.5) 161/217 (74.2) 19/28 (67.9)
13 (56.5) 232 (63.2) 240 (67.6) 37 (68.5)
10 (43.5) 135 (36.8) 115 (32.4) 17 (31.5)
16 (69.6) 291 (78.6) 272 (76.0) 38 (70.4)
tion; BMI, body mass index; ICU, intensive care unit; APACHE, Acute Physiology and
 obstructive pulmonary disease.
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Data were collected and evaluated as described in Bassetti
et al. [16].
2.3. Clinical outcome
Clinical outcome was assessed by the investigator at the end of
treatment or on discharge. Definitions of clinical outcome are as
described in Bassetti et al. [16].
2.4. Safety
The number of adverse events (AEs), serious AEs and premature
discontinuations as well as all-causality mortality occurring at any
time during the study, including the follow-up period, were
recorded. A detailed description of the criteria for assessment of
safety is available in Guirao et al. [18].
2.5. Statistical analysis
Statistical differences in the distribution of baseline
characteristics among the three age groups were assessed
using one-way analysis of variance (ANOVA) for continuous
variables and χ2 test for categorical variables. Descriptive
statistics included relative frequencies for categorical variables,
and mean  standard deviation or median (interquartile range) for
continuous variables. A pooled analysis of patient-level data from
the five studies was conducted for selected characteristics. The χ2
test was used to determine whether an association existed
between age group and response to treatment. Data were analysed
in tabulated summaries with the number of patients with
available (i.e. non-missing) data as the denominator. Diagnoses
of cSSTI and cIAI were mutually exclusive for inclusion, although
patients could have other simultaneous infections. AEs were
tabulated by the Medical Dictionary for Regulatory Activities
(MedDRA) preferred term. All-causality mortality was analysed by
indication and by disease severity score using the Acute Physiology
and Chronic Health Evaluation (APACHE) II and/or Sequential





A total of 1782 patients received at least one dose of
tigecycline at 191 geographic sites across the five observational
studies. The results of the five studies were pooled and the total
population was divided into three age categories: <65 years
(804 patients); 65–80 years (836 patients); and >80 years (139
patients). Data were unknown/missing from 3 patients (0.2%) in
the overall population; all of these patients were in the cIAI
population (0.4%). Over one-half of the total patient population
from these pooled studies was aged 65 years [975/1779 (non-
missing data only); 54.8%].
Males represented 61.4% of the total population; however,
males accounted for a smaller proportion of the total as the age
group increased (63.4% of the <65 years age group, 62.0% of the
65–80 years age group and 48.2% of the >80 years age group),
probably due to lower life expectancy. Mean body mass index
(BMI) in the total pooled population was 27.5  6.5 kg/m2
(range 14–90 kg/m2) [16]. BMI was highest in the 65–80
years group (28.0 kg/m2) and lowest in the >80 years group
(26.7 kg/m2).3.1.2. Indications
Within each age group, the population was divided into three
categories based on infection type, namely cIAI, cSSTI and total,
the latter including patients who received tigecycline for any
indication (Table 1; data for the total population are not shown).
The most frequent indications for prescription of tigecycline were
cIAI (785 patients) and cSSTI (254 patients), together represent-
ing 58.3% of the total pooled population. Other diagnoses for
which patients received tigecycline included pneumonia, blood-
stream infection and sepsis-related conditions [16]. Of the cIAI
patients, the most common diagnosis was generalised peritonitis
(51.2%) and the most common type among these patients was
secondary peritonitis (65.7%). Many infections were secondary to
perforation of the colon or rectum (41.4%), and 94.8% required
surgery [17]. For the cSSTI patients, the most common diagnosis
was necrotizing infection (43.8%) and the majority had deep soft-
tissue infections (75.5%), with 69.0% requiring surgical interven-
tion [10]. The age distribution of patients was similar in the cIAI
and cSSTI groups (Table 1).
3.1.3. Severity of illness
For cIAI, ICU admission was highest in the 65–80 years age
group (59.7%) and lowest in the >80 years age group (50.0%); for
cSSTI, ICU admission was highest in those aged <65 years (36.2%)
and lowest in those aged 65–80 (33.3%). The APACHE II and SOFA
scores documented before tigecycline treatment in this patient
cohort confirmed a particularly high level of disease severity [16].
APACHE II scores were collected in 205 cSSTI and 614 cIAI patients
in the studies from Germany, Italy, Spain-1 and Spain-2. Overall
mean scores in these patients were 15.0  7.9 and 16.9  7.6,
respectively. SOFA scores were documented for 32 cSSTI and 108
cIAI patients in France and Spain-2, and the overall mean scores in
these patients were 5.8  3.9 and 7.0  4.2, respectively [18].
3.1.4. Co-morbidities
Co-morbidities were present in 90.9% of cSSTI patients (the
most common being hypertension, diabetes mellitus and arterio-
sclerosis) [8]. Co-morbidities were present in a similar proportion
of cIAI patients (87.4%; the most common being hypertension,
diabetes mellitus and neoplasia) [17]. There was a trend for a
higher proportion of patients aged 65 years having at least one
co-morbidity compared with those aged <65 years (86.8% vs. 93.5%
vs. 93.5% for those aged <65, 65–80 and >80 years, respectively).
The most common co-morbid conditions in each age group are
shown in Table 1.
3.1.5. Baseline pathogens
Pathogens identified at baseline are shown in Table 1. No clear
association was identified between age group and the likelihood of
having a polymicrobial infection. Patients in the >80 years age
group with cIAI were somewhat less likely to have an anaerobe
identified at baseline (7.1% for >80 years vs. 25.9% for <65 years),
whilst in the overall population patients in the 65–80 years age
group were somewhat more likely to have a resistant pathogen
(46.1% for 65–80 years vs. 39.3% and 39.8% for <65 years and >80
years age groups, respectively).
3.1.6. Site of infection acquisition
For cSSTI, an equal proportion of patients in the <65 years age
group had nosocomial and community-acquired infection (both
50.0%) (Table 1). However, both in the 65–80 years and >80 years
age groups there was a bias towards nosocomial acquisition (58.8%
nosocomial vs. 41.2% community-acquired infection for 65–80
years and 56.5% nosocomial vs. 43.5% community-acquired
infection for >80 years). By contrast, in the cIAI group, among
those patients aged <65 years a larger proportion had a nosocomial
202 M. Bassetti et al. / Journal of Global Antimicrobial Resistance 18 (2019) 199–206infection (63.2% nosocomial vs. 36.8% community-acquired). This
trend became more pronounced in advanced age (67.6% nosoco-
mial vs. 32.4% community-acquired for 65–80 years and 68.5%
nosocomial vs. 31.5% community for >80 years age groups).
3.1.7. Previous antibiotic therapy
The majority of patients in these studies had a history of prior
antibacterial therapy (80.2%). The likelihood of having received
previous antibiotic therapy decreased with increasing age (81.3%
vs. 79.8% vs. 76.3% for those aged <65, 65–80 and >80 years,
respectively), as shown in Table 1.
Further details on baseline demographic and clinical character-
istics are provided in Montravers et al. [8] and Eckmann et al. [17].
3.1.8. Use of tigecycline: dosing
The majority (>90%) of cSSTI and cIAI patients in the
observational studies received the standard dosage of tigecy-
cline, and the mean duration of tigecycline treatment was
12.0  7.0 days and 10.6  6.1 days for cSSTI and cIAI, respec-
tively [18]. In the current analysis, no clear association was
noted between age group and decision to prescribe the standard
dose of tigecycline in the total pooled population or in the cSSTI
group. However, in the cIAI group standard-dose prescription
was higher than average among patients aged >80 years (89.2%).
There was a slight trend towards shorter duration of therapy
with increased age in the total pooled population: 11.3 days
for <65 years vs. 10.6 days for >80 years.
Tigecycline was administered first-line to 44.4% of cSSTI
patients and 48.7% of cIAI patients [18]. There was no clear
association between line of therapy (first- versus second-line) and
age when all infection types were considered. However, for cIAI a
greater percentage of patients received first-line tigecycline
therapy in the older age category (54.1% for >80 years vs. 38.0%
for <65 years). More patients received tigecycline monotherapy
compared with combination therapy overall, and monotherapy
was more widely used with increasing age. Combination therapy
was more prevalent among patients treated for cIAI than for cSSTI;
cIAI patients aged <65 years were most likely to receive
combination therapy (49.2%), whilst cSSTI patients aged 65–80
years were least likely to receive combination therapy (24.6%).
3.1.9. Reasons for tigecycline use
The most frequently cited reasons for prescription of tigecycline
in all age groups were as follows.Table 2
Clinical response of patients included in the analysis.
Response cSSTI (N = 254) 
<65 years (n = 117) 65–80 years (n = 114) >80
n (%) N n (%) N n (%
Overall response
Non-responder 9 (8.7) 104 15 (14.3) 105 3 (1
Responder 83 (79.8) 84 (80.0) 16 
Indeterminate 12 (11.5) 6 (5.7) 2 (9
By severity of disease
APACHE II score >15 (responder) 28 (80.0) 35 29 (70.7) 41 4 (8
By site of infection acquisition
Nosocomial (responder) 38 (73.1) 52 49 (77.8) 63 9 (6
Community (responder) 44 (86.3) 51 35 (83.3) 42 7 (8
By therapy type
Combination (responder) 21 (67.7) 31 15 (57.7) 26 4 (6
Monotherapy (responder) 62 (84.9) 73 69 (89.6) 77 12 
Empirical (responder) 21 (87.5) 24 28 (87.5) 32 7 (7
Targeted (responder) 25 (75.8) 33 31 (77.5) 40 4 (1
First-line (responder) 27 (79.4) 34 32 (88.9) 36 6 (1
cSSTI, complicated skin and soft-tissue infection; cIAI, complicated intra-abdominal in  Broad pathogen spectrum: cSSTI, 50.6%, 43.0% and 62.5% for
<65, 65–80 and >80% years, respectively; and cIAI, 45.9%,
54.3% and 48.5% for <65, 65–80 and >80% years, respectively.
 Failure of previous therapy: cSSTI, 43.5%, 54.4% and 56.3% for
<65, 65–80 and >80% years, respectively; and cIAI, 48.0%,
41.7% and 37.8% for <65, 65–80 and >80% years, respectively.
 Polymicrobial infection: cSSTI, 38.5%, 75.0% and 0% for <65,
65–80 and >80% years, respectively; and cIAI, 73.0%, 67.6% and
100.0% for <65, 65–80 and >80% years, respectively.
 Suspected or identified resistant pathogen: cSSTI, 43.5%, 51.1%
and 37.5% for <65, 65–80 and >80% years, respectively; and




In the cSSTI group, patients aged 80 years showed higher
response rates (79.8% and 80.0% for <65 years and 65–80 years age
groups, respectively, vs. 76.2% for >80 years). Similar results were
seen in the cIAI group (81.1% and 75.2% for <65 years and 65–80
years age groups, respectively, vs. 69.2% for >80 years). In the cSSTI
group there was a particularly high proportion of responders
among the >80 years group (76.2%) (Table 2). Overall, the youngest
patients (<65 years) showed the best response to treatment;
however, almost 70% of the >80 age group were classified as
responders to tigecycline at the end of treatment (74.7% for <65
years, 73.6% for 65–80 years and 69.7% for >80% years; data not
shown). Marginally more patients in the oldest age group (>80
years) were classified as having an indeterminate response (9.2%
for <65 years, 10.7% for 65–80 years and 11.5% for >80% years).
Analysis of the response rates in the different age groups showed
no statistical association between age group and response (χ2 P-
value = 0.706).
Among those patients with an APACHE II score >15, response
rates declined slightly with increasing age in the cIAI group (80.2%
for <65 years, 73.2% for 65–80 years and 73.3% for >80 years), and
decreased in the cSSTI group between the <65 years and 65–80
years age groups (80.0% vs. 70.7%, respectively).
3.2.2. Clinical response by site of infection acquisition
Community-acquired infections were associated with better
clinical response across all age groups compared with nosocomialcIAI (N = 785)
 years (n = 23) <65 years (n = 370) 65–80 years (n = 358) >80 years (n = 54)
) N n (%) N n (%) N n (%) N
4.3) 21 44 (13.0) 339 51 (15.0) 339 9 (17.3) 52
(76.2) 275 (81.1) 255 (75.2) 36 (69.2)
.5) 20 (5.9) 33 (9.7) 7 (13.5)
0.0) 5 105 (80.2) 131 123 (73.2) 168 22 (73.3) 30
9.2) 13 164 (78.8) 208 164 (73.2) 224 25 (67.6) 37
7.5) 8 109 (85.2) 128 89 (79.5) 112 11 (73.3) 15
6.7) 6 125 (76.7) 163 102 (70.8) 144 11 (68.8) 16
(80.0) 15 150 (85.2) 176 153 (78.5) 195 25 (69.4) 36
7.8) 9 86 (80.4) 107 73 (69.5) 105 8 (61.5) 13
00.0) 4 44 (77.2) 57 62 (82.7) 75 10 (71.4) 14
00.0) 6 74 (83.1) 89 86 (72.3) 119 13 (68.4) 19
fection; APACHE, Acute Physiology and Chronic Health Evaluation.
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group of the total pooled population (64.0% nosocomial responders
vs. 82.4% community responders) (Fig. 1). The relationship
between site of infection acquisition and clinical response was
similar in the cIAI and cSSTI groups, with the difference between
nosocomial and community-acquired infection being most pro-
nounced in the cSSTI group (Table 2).
3.2.3. Tigecycline therapy
Tigecycline was prescribed as monotherapy in 181 (71.8%)
cSSTI patients and 430 (54.8%) cIAI patients [18]. The likelihood
of being prescribed tigecycline monotherapy increased with age
in the total pooled population (41.6% for <65 years, 52.9% for 65–
80 years and 59.0% for >80 years), a trend that was reflected
both in the cSSTI and cIAI groups (see Table 2). Tigecycline
monotherapy was associated with a better response rate
compared with combination therapy for all age groups
(Fig. 2). Monotherapy also appeared to be related to improved
clinical response compared with combination therapy both in
the cIAI and cSSTI groups, with a more pronounced difference
observed in the cSSTI group (Fig. 2). There was no clear
association between empirical versus targeted therapy in terms
of clinical response across the age groups (Table 2).
3.3. Adverse events and mortality
Patients with cIAI appeared to be at greater risk for all types of
AE compared with those with cSSTI, particularly in the 65–80 years
and >80 years age groups (Table 3). Discontinuation due to an AE
did not show any clear association with any age group. Total
discontinuations were higher in the >80 age group compared with
the younger age groups (cSSTI, 25.0% for >80 years vs. 18.7% and
18.0% for <65 years and 65–80 years, respectively; and cIAI, 45.9%
for >80 years vs. 22.9% and 29.6% for <65 years and 65–80 years,
respectively).
All-cause mortality observed in the total pooled population
treated with tigecycline alone or in combination with other
therapies was 9.4% for those with cSSTI and 18.6% for those with
cIAI [18]. Overall, there was a trend towards higher mortality with
increasing age, which was more pronounced in the cIAI group
(13.8% for <65 years, 21.8% for 65–80 years and 31.5% for >80 years)
than in the cSSTI group (9.4% for <65 years, 9.6% for 65–80 years
and 8.7% for >80 years). Rates of overall mortality and mortality
due to an AE were higher for patients with cIAI than those with
cSSTI (Table 3).Fig. 1. Tigecycline age analysis by site of infection acquisition (nosocomial versus comm
intra-abdominal infection.4. Discussion
In this analysis, use of tigecycline was investigated in different
age groups (N = 1782 patients) in real-life clinical practice in five
observational studies in four European countries.
Overall, the patient population in these observational studies
was representative of that seen in clinical practice; many had an
APACHE II or SOFA score indicative of severe disease, most had
previously been treated with other antibiotics, and the majority
suffered from co-morbidities.
Over one-half of the total patient population from these pooled
studies was 65 years of age, meaning that this study represents
an older population than is typically included in clinical trials and
more closely resembles the patients likely to receive tigecycline for
cIAI or cSSTI in clinical practice. The relatively small number (n
= 139) of patients in the >80 years age group limits interpretation
of the observations from this analysis but is to be expected based
on general population demographics. Likewise, the lower repre-
sentation of males in the higher age groups is equally unsurprising
considering the typically lower life expectancy for males [20].
The higher frequency of co-morbidities observed among
patients aged 65 years reflects the frequency of co-morbidities
in the elderly reported widely in the literature [21]. The lower rate
of smoking with increasing age may be related to the lower life
expectancy of people who smoke, who may therefore be less likely
to reach 80 years of age [22]. The equal split between nosocomial
and community-acquired infections in the cSSTI group is in
accordance with other reports in the literature [11].
Overall, this analysis indicates that tigecycline is a rational
therapy choice in very elderly patients for the treatment both of
cIAIs and cSSTIs despite the previously mentioned challenges of
immune degradation, increased risk of drug-resistant infection,
atypical signs of infection, co-morbidities and vulnerability to AEs.
As a greater percentage of patients received first-line tigecycline
therapy in the older age category (for cIAI), it is possible that
tigecycline was the drug of choice in these patients to reduce the
risk of treatment failure due to resistance. Clinical response rates in
those aged >80 years, although slightly lower than in younger
patients, perhaps due to the higher rate of polymicrobial infection
in the older group, remain high with no statistically significant
differences from the other age groups. This finding differs from
experience elsewhere in the literature where a clear relationship
between older age and persistence of infection has been shown
[23]. Those patients receiving monotherapy as opposed to
combination therapy achieved better clinical response rates;unity-acquired). cSSTI, complicated skin and soft-tissue infection; cIAI, complicated
Fig. 2. Tigecycline age analysis by type of therapy (monotherapy versus combination therapy). cSSTI, complicated skin and soft-tissue infection; cIAI, complicated intra-
abdominal infection.
Table 3
Adverse events of patients included in the analysis.
cSSTI (N = 254) cIAI (N = 785)
<65 years (n = 117) 65–80 years (n = 114) >80 years (n = 23) <65 years (n = 370) 65–80 years (n = 358) >80 years (n = 54)
n (%) N n (%) N n (%) N n (%) N n (%) N n (%) N
Adverse events (AEs)
Total no. of AEs 46 92 37 90 7 16 208 279 240 271 46 37
Patients with AEs 27 (29.3) 17 (18.9) 5 (31.3) 89 (31.9) 113 (41.7) 19 (51.4)
Patients with serious AEs 15 (16.3) 12 (13.3) 2 (12.5) 58 (20.8) 77 (28.4) 15 (40.5)
Patients with severe AEs 14 (15.2) 4 (4.4) 1 (6.3) 36 (12.9) 45 (16.6) 13 (35.1)
Deaths due to AEs 10 (10.9) 7 (7.8) 2 (12.5) 36 (12.9) 59 (21.8) 12 (32.4)
Discontinuation due to AE 7 (7.6) 3 (3.3) 1 (6.3) 24 (8.6) 22 (8.1) 6 (16.2)
Overall mortality
Total no. of deaths 11 (9.4) 117 11 (9.6) 115 2 (8.7) 23 51 (13.8) 370 78 (21.8) 358 17 (31.5) 54
Total discontinuations 17 (18.7) 91 16 (18.0) 89 4 (25.0) 16 64 (22.9) 279 80 (29.6) 270 17 (45.9) 37
AE 3 (17.6) 17 2 (12.5) 16 1 (25.0) 4 3 (4.7) 64 7 (8.9) 80 3 (17.6) 17
Treatment failure 6 (35.3) 8 (50.0) 0 28 (43.8) 18 (22.8) 4 (23.5)
Death 6 (35.3) 2 (12.5) 1 (25.0) 13 (20.3) 27 (34.2) 5 (29.4)
Microbiological failure 1 (5.9) 0 0 9 (14.1) 17 (21.5) 3 (17.6)
Others 1 (5.9) 4 (25.0) 2 (50.0) 16 (25.0) 18 (22.8) 2 (11.8)
cSSTI, complicated skin and soft-tissue infection; cIAI, complicated intra-abdominal infection.
204 M. Bassetti et al. / Journal of Global Antimicrobial Resistance 18 (2019) 199–206however, this could be due to patients with cIAI being more
severely ill than those with cSSTI rather than a direct result of the
combination therapy. In this study, nosocomial infections were
associated with a lower clinical response, which may be related to
a host who has severe health concerns. Overall, responses with
tigecycline in the elderly were better for those patients who had
cSSTI compared with those who had cIAI (76.2% responders in the
>80 years group for cSSTI vs. 69.2% for cIAI).
The rates of all classes of AEs and mortality increased with
advancing age. The main serious AEs leading to death in cSSTI and
cIAI patients were multiorgan failure and progression to sepsis and
septic shock. More AEs were seen among patients with cIAI; this
may be due to differences in the severity of infection or may reflect
the fact that more patients with cSSTI received monotherapy. The
non-comparative, non-controlled nature of these observational
studies makes it unfeasible to infer causality for the drug regimen
used. Nevertheless, it seems clear that an unfavourable outcome of
multiorgan failure or sepsis might be related to variables that are
independent of treatment; indeed, the delayed management of
elderly patients is also a well-known cause of multiorgan failure
and septic shock [24]. For example, pre-treatment APACHE II and
SOFA scores were closely correlated with mortality, and many
patients in these studies had co-morbid conditions and severe
infections and/or were critically ill in the ICU. For details about theAEs recorded during these studies and further data on mortality,
refer to Guirao et al. [18].
The observational nature of this analysis limits interpretation
and the results should be viewed as descriptive only as there was
no control group of patients not treated with tigecycline in this
assessment. Furthermore, the data can be complex to interpret,
particularly given the heterogeneity of patient populations and
the differences across the studies in the prescription of
tigecycline. Treatment decisions were at the discretion of the
treating physician and were non-adjudicated. The patient
population was heterogeneous, with different hospital settings
and different inclusion/exclusion terms for the five separate
studies. Stratification of the total population into three age groups
meant that the >80 years age group was small and the
conclusions relating to this age group should therefore be viewed
with caution. A further limitation is that no pharmacokinetic/
pharmacodynamic (PK/PD) data could be provided for this
analysis owing to the observational nature of the study; these
data are warranted in future trials to accurately define the PK/PD
changes in the elderly.
In summary, when tigecycline is used for the treatment of
cSSTIs and cIAIs, and at the correct dosage, the results reported in
this analysis were associated with a favourable outcome consider-
ing the characteristics of the patient population included. This
M. Bassetti et al. / Journal of Global Antimicrobial Resistance 18 (2019) 199–206 205analysis provides useful data to support clinical decision-making
around the use of antibiotics in elderly populations.
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